Comparator: Placebo to efavirenz — Competitive Intelligence Brief

Comparator: Placebo to efavirenz (Comparator: Placebo to efavirenz) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-nucleoside reverse transcriptase inhibitor (NNRTI). Area: Infectious Disease / Virology.

phase 3 Non-nucleoside reverse transcriptase inhibitor (NNRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Comparator: Placebo to efavirenz (Comparator: Placebo to efavirenz) — Merck Sharp & Dohme LLC. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase to prevent viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Comparator: Placebo to efavirenz TARGET	Comparator: Placebo to efavirenz	Merck Sharp & Dohme LLC	phase 3	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV reverse transcriptase
Highly active antiretroviral therapy	Highly active antiretroviral therapy	PETHEMA Foundation	marketed	Antiretroviral combination therapy	HIV reverse transcriptase, HIV protease, HIV integrase (depending on regimen composition)
Immediate switch to TDF/FTC/RPV	Immediate switch to TDF/FTC/RPV	Azienda Ospedaliera San Gerardo di Monza	marketed	Antiretroviral combination therapy (NRTI/NNRTI)	HIV reverse transcriptase, HIV integrase
3TC	3TC	Avexa	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase; hepatitis B polymerase
Truvada Pill	Truvada Pill	University of North Carolina, Chapel Hill	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
tenofovir disproxil fumarate/emtricitabine	tenofovir disproxil fumarate/emtricitabine	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor combination	HIV reverse transcriptase
Darunavir / Ritonavir + Tenofovir / Emtricitabine	Darunavir / Ritonavir + Tenofovir / Emtricitabine	Juan A. Arnaiz	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-nucleoside reverse transcriptase inhibitor (NNRTI) class)

1. ViiV Healthcare · 4 drugs in this class
2. National Institute of Allergy and Infectious Diseases (NIAID) · 3 drugs in this class
3. Merck Sharp & Dohme LLC · 2 drugs in this class
4. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
5. Germans Trias i Pujol Hospital · 1 drug in this class
6. International Partnership for Microbicides, Inc. · 1 drug in this class
7. Janssen Infectious Diseases BVBA · 1 drug in this class
8. Janssen-Cilag S.p.A. · 1 drug in this class
9. Johns Hopkins Bloomberg School of Public Health · 1 drug in this class
10. Tibotec Pharmaceuticals, Ireland · 1 drug in this class